In this study, we assessed whether polymorphisms in genes of NER pathway, including ERCC5, ERCC6, MMS19L, CCNH, XPC and RRM1, are associated with affecting the tolerability of platinum-based chemotherapy in stage IIIB and IV NSCLC patients. This evidence concerns the gene MMS19 and non-small cell lung carcinoma.